vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $1.6M, roughly 3.0× bioAffinity Technologies, Inc.). bioAffinity Technologies, Inc. runs the higher net margin — -197.0% vs -200.5%, a 3.5% gap on every dollar of revenue. On growth, MAXCYTE, INC. posted the faster year-over-year revenue change (-20.9% vs -27.8%). bioAffinity Technologies, Inc. produced more free cash flow last quarter ($-2.6M vs $-2.9M). Over the past eight quarters, MAXCYTE, INC.'s revenue compounded faster (-7.4% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
BIAF vs MXCT — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $4.8M |
| Net Profit | $-3.1M | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | -196.9% | -234.5% |
| Net Margin | -197.0% | -200.5% |
| Revenue YoY | -27.8% | -20.9% |
| Net Profit YoY | -5.7% | 9.4% |
| EPS (diluted) | $-3.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $4.8M | ||
| Q3 25 | $1.4M | $4.6M | ||
| Q2 25 | $1.3M | $5.8M | ||
| Q1 25 | $1.9M | $5.7M | ||
| Q4 24 | $2.2M | $6.1M | ||
| Q3 24 | $2.4M | $5.6M | ||
| Q2 24 | $2.4M | $5.0M | ||
| Q1 24 | $2.4M | $5.6M |
| Q4 25 | $-3.1M | $-9.6M | ||
| Q3 25 | $-5.1M | $-12.4M | ||
| Q2 25 | $-4.1M | $-12.4M | ||
| Q1 25 | $-2.7M | $-10.3M | ||
| Q4 24 | $-3.0M | $-10.6M | ||
| Q3 24 | $-2.0M | $-11.6M | ||
| Q2 24 | $-2.1M | $-9.4M | ||
| Q1 24 | $-2.0M | $-9.5M |
| Q4 25 | -196.9% | -234.5% | ||
| Q3 25 | -158.6% | -307.4% | ||
| Q2 25 | -198.2% | -244.3% | ||
| Q1 25 | -141.7% | -214.1% | ||
| Q4 24 | -133.5% | -213.1% | ||
| Q3 24 | -84.0% | -250.4% | ||
| Q2 24 | -87.1% | -241.0% | ||
| Q1 24 | -80.8% | -219.8% |
| Q4 25 | -197.0% | -200.5% | ||
| Q3 25 | -349.3% | -269.7% | ||
| Q2 25 | -319.9% | -212.2% | ||
| Q1 25 | -143.5% | -178.7% | ||
| Q4 24 | -134.4% | -175.0% | ||
| Q3 24 | -85.1% | -205.9% | ||
| Q2 24 | -88.0% | -188.8% | ||
| Q1 24 | -81.5% | -170.6% |
| Q4 25 | $-3.59 | — | ||
| Q3 25 | $-4.74 | $-0.12 | ||
| Q2 25 | $-0.17 | $-0.12 | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-17.27 | — | ||
| Q3 24 | $-4.84 | $-0.11 | ||
| Q2 24 | $-0.19 | $-0.09 | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $171.5M |
| Total Assets | $11.0M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $103.0M | ||
| Q3 25 | $7.7M | $105.7M | ||
| Q2 25 | $802.8K | $126.6M | ||
| Q1 25 | $444.7K | $138.3M | ||
| Q4 24 | $1.1M | $154.5M | ||
| Q3 24 | $756.6K | $153.8M | ||
| Q2 24 | $801.3K | $157.3M | ||
| Q1 24 | $2.5M | $157.5M |
| Q4 25 | $7.3M | $171.5M | ||
| Q3 25 | $8.9M | $180.3M | ||
| Q2 25 | $-2.1M | $190.7M | ||
| Q1 25 | $1.4M | $199.4M | ||
| Q4 24 | $2.6M | $206.3M | ||
| Q3 24 | $3.1M | $213.3M | ||
| Q2 24 | $3.4M | $221.3M | ||
| Q1 24 | $5.3M | $226.4M |
| Q4 25 | $11.0M | $202.5M | ||
| Q3 25 | $11.5M | $213.5M | ||
| Q2 25 | $4.8M | $219.8M | ||
| Q1 25 | $5.5M | $230.0M | ||
| Q4 24 | $6.5M | $239.5M | ||
| Q3 24 | $6.6M | $248.6M | ||
| Q2 24 | $6.7M | $251.5M | ||
| Q1 24 | $8.0M | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-2.7M |
| Free Cash FlowOCF − Capex | $-2.6M | $-2.9M |
| FCF MarginFCF / Revenue | -160.7% | -61.0% |
| Capex IntensityCapex / Revenue | 0.0% | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $-2.7M | ||
| Q3 25 | $-2.5M | $-7.5M | ||
| Q2 25 | $-2.6M | $-9.9M | ||
| Q1 25 | $-1.6M | $-14.4M | ||
| Q4 24 | $-1.7M | $-7.8M | ||
| Q3 24 | $-1.7M | $-4.4M | ||
| Q2 24 | $-1.5M | $-4.8M | ||
| Q1 24 | $-2.3M | $-10.6M |
| Q4 25 | $-2.6M | $-2.9M | ||
| Q3 25 | $-2.5M | $-7.8M | ||
| Q2 25 | $-2.7M | $-10.4M | ||
| Q1 25 | $-1.7M | $-15.1M | ||
| Q4 24 | $-1.7M | $-8.0M | ||
| Q3 24 | $-1.7M | $-4.8M | ||
| Q2 24 | $-1.6M | $-5.1M | ||
| Q1 24 | $-2.4M | $-11.4M |
| Q4 25 | -160.7% | -61.0% | ||
| Q3 25 | -171.8% | -168.5% | ||
| Q2 25 | -209.6% | -179.2% | ||
| Q1 25 | -91.3% | -262.3% | ||
| Q4 24 | -76.0% | -131.6% | ||
| Q3 24 | -73.1% | -85.5% | ||
| Q2 24 | -65.1% | -103.3% | ||
| Q1 24 | -99.2% | -203.6% |
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.3% | 6.5% | ||
| Q2 25 | 1.1% | 10.0% | ||
| Q1 25 | 2.7% | 11.4% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.4% | 7.2% | ||
| Q2 24 | 1.2% | 5.9% | ||
| Q1 24 | 1.7% | 14.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
